Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alvaro, T
Right arrow Articles by Piris, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alvaro, T
Right arrow Articles by Piris, M.
Haematologica, Vol 91, Issue 12, 1605-1612
Copyright © 2006 by Ferrata Storti Foundation


Comparative Study

The presence of STAT1-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma

T Alvaro, M Lejeune, FI Camacho, MT Salvado, L Sanchez, JF Garcia, C Lopez, J Jaen, R Bosch, LE Pons, C Bellas, and MA Piris

Department of Pathology, Hospital de Tortosa Verge de la Cinta, C/ Esplanetes n.14, 43500-Tortosa, Spain. talvaro.htvc.ics@gencat.net

BACKGROUND AND OBJECTIVES: The presence of tumor-associated macrophages (TAM) is a prognostic factor for survival in follicular lymphoma (FL). Overexpression and/or activation of the signal transducer and activator of transcription 1 (STAT1) in these TAM have also been observed. The aim of this study was to determine the extent to which macrophages are present in FL and to investigate the expression of STAT1 in these cells. DESIGN AND METHODS: We retrospectively analyzed 211 patients with distinct stages and grades of FL. Expression of the CD68 proteins, chosen as a marker for macrophages, and STAT1 was quantified by immunohistochemistry and double immunofluorescence. RESULTS: Automated determinations revealed the presence of CD68-positive macrophages in all FL tissues studied (mean 57.6+/-45.1 cells/field), while STAT1 protein was expressed in 29.94% of cases. Double-fluorescence staining confirmed that STAT1 protein co-localized exclusively with CD68, indicating the presence of a subset of STAT1-expressing TAM localized principally in the vicinity of tumor cells. Multivariate analysis showed that, besides the Follicular Lymphoma International Prognostic Index (FLIPI) classification, expression of STAT1 was an important independent prognostic factor for shorter overall survival in FL. INTERPRETATION AND CONCLUSIONS: These results demonstrate the presence of STAT1-expressing TAM in FL and their association with an adverse outcome, thus emphasizing the relevance of non-tumor cells in the control of the growth and survival of lymphoma cells.


This article has been cited by other articles:


Home page
haematolHome page
M. Lejeune and T. Alvaro
Clinicobiological, prognostic and therapeutic implications of the tumor microenvironment in follicular lymphoma
Haematologica, January 1, 2009; 94(1): 16 - 21.
[Full Text] [PDF]


Home page
J. Am. Med. Inform. Assoc.Home page
C. Lopez, M. Lejeune, P. Escriva, R. Bosch, M. T. Salvado, L. E. Pons, J. Baucells, X. Cugat, T. Alvaro, and J. Jaen
Effects of Image Compression on Automatic Count of Immunohistochemically Stained Nuclei in Digital Images
J. Am. Med. Inform. Assoc., November 1, 2008; 15(6): 794 - 798.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
P. P. Piccaluga, A. Califano, U. Klein, C. Agostinelli, B. Bellosillo, E. Gimeno, S. Serrano, F. Sole, Y. Zang, B. Falini, et al.
Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas
Haematologica, July 1, 2008; 93(7): 1033 - 1038.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Taskinen, M.-L. Karjalainen-Lindsberg, and S. Leppa
Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP
Blood, May 1, 2008; 111(9): 4664 - 4667.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. Canioni, G. Salles, N. Mounier, N. Brousse, M. Keuppens, F. Morchhauser, T. Lamy, A. Sonet, M.-C. Rousselet, C. Foussard, et al.
High Numbers of Tumor-Associated Macrophages Have an Adverse Prognostic Value That Can Be Circumvented by Rituximab in Patients With Follicular Lymphoma Enrolled Onto the GELA-GOELAMS FL-2000 Trial
J. Clin. Oncol., January 20, 2008; 26(3): 440 - 446.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Taskinen, M.-L. Karjalainen-Lindsberg, H. Nyman, L.-M. Eerola, and S. Leppa
A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-Prednisone
Clin. Cancer Res., October 1, 2007; 13(19): 5784 - 5789.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. Alvaro, M. Lejeune, M.-T. Salvado, C. Lopez, P. Escriva, J. Jaen, R. Bosch, and L. E. Pons
In Reply
J. Clin. Oncol., April 1, 2007; 25(10): 1291 - 1292.
[Full Text] [PDF]


Home page
ASH Education BookHome page
G. A. Salles
Clinical Features, Prognosis and Treatment of Follicular Lymphoma
Hematology, January 1, 2007; 2007(1): 216 - 225.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.